Malaysia’s Unexpected Health Reform Program
After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt…
Patrick is the managing editor of PharmaBoardroom
After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt…
In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit…
Egypt continues to struggle with fake drugs reaching the hands of patients as the suppliers of counterfeit medicines become more sophisticated by adding company logos to packaging. The Egyptian police…
The Health Committee of the Egyptian House of Representatives is preparing to discuss a draft law from the government on the establishment of the “Egyptian Drug Authority.” The new…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in Canadian pharma’s industry, regulatory affairs, reimbursement and pricing. The Honourable Ginette Petitpas Taylor Minister of Health The…
Egypt has found a way to profit from the country’s access to cheap Hep C drugs by offering package holidays to tourists suffering from the disease, but the ‘tour and…
With the highest rate of Hepatitis C on the planet, Egypt is now making great efforts to eradicate the disease in the north MENA regions. Hep C is a disease…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
China is set to become the second largest market for Mundipharma’s OxyContin behind the US. It comes as no surprise that sales of opioids such as OxyContin have plummeted…
Against an alluring backdrop, big-name pharma brands are now starting to spend heavily on in-country manufacturing, development and shared service facilities in Spain. Spain has exceedingly high youth unemployment.…
See our Cookie Privacy Policy Here
